Trizen Medical completes third funding round in a year with Series B+, pacing China’s medical LLM race

One of China's earliest innovators in fine-tuning large language models (LLMs) for medical applications and developing AI physician assistants, Hangzhou Trizen Medical Technology Co., Ltd. ("Trizen Medical"), has officially announced the completion of a tens of millions of RMB Series B+ financing round. This round was led by Puhua Capital, with Probe Capital serving as the exclusive financial advisor. The raised capital will be invested in the deep R&D of its core product, the "Trizen Medical LLM and Clinical Application Platform", accelerate cooperative promotion targeting hospitals and physicians, and initiate plans for overseas market expansion.

This financing marks Trizen Medical's third funding round within approximately one year, setting a new record for fundraising speed among Chinese medical LLM companies. It also clearly reflects a shift in the capital market's focus within medical AI—from a pure "technology race" towards a deeper evaluation of commercialization capabilities and tangible clinical value.

Since 2024, the global medical AI sector has remained highly active, with valuations of generative AI healthcare companies like the U.S.-based Abridge and Open Evidence continuing to rise. The underlying rationale is that a valuable medical large language model must be deeply embedded in and optimize the actual "clinical workflow."

In China, Trizen Medical exemplifies this philosophy. Founded by Dr. Chong Xue, who holds an M.D. in Surgery from the Chinese Academy of Medical Sciences & Peking Union Medical College and completed postdoctoral research at the Johns Hopkins University School of Medicine, the company has long been committed to leveraging AI technologies, particularly large language models, to provide world-class intelligent solutions for physicians and patient groups. It stands as one of China's earliest innovators in fine-tuning medical LLMs and developing AI physician assistant applications.

Prior to this round, Trizen Medical had secured strategic investment from the A-share listed company Innovative Medical (SZ.002173) and Series B investment from the Good Doctor Group. The intensive backing across three rounds within a year—from both industrial and institutional investors—not only demonstrates strong industry and market recognition of Trizen Medical's technical roadmap and commercialization capabilities but also reflects robust confidence in China's potential to birth a world-class medical AI company—a "Chinese version of Abridge."

At a time when the industry broadly faces challenges of "difficult implementation and monetization," Trizen Medical has delivered an impressive commercial performance. Its self-developed Trizen Medical LLM and application product, "Trizen AI," has demonstrated strong momentum in core scenarios such as "Intelligent Medical Documentation" and "Patient Services." In 2025, the company achieved a commanding lead in contracted value within these domains, with projected growth reaching 12 to 15 times the total figure for 2024. Alongside this business expansion, the number of physician users has grown exponentially. Trizen Medical has thus established itself as a benchmark case in China's medical AI field for achieving large-scale, commercially viable closed-loop implementation.